Your session is about to expire
← Back to Search
Pembrolizumab for Breast Cancer
Study Summary
This trial is studying a combination of immunotherapy and hormone therapy to better control estrogen receptor positive breast cancer.
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA sanctioned Pembrolizumab for medical use?
"Based on the available clinical data, our team at Power has assigned a score of 2 for pembrolizumab's safety rating. This is due to it being classified as a Phase 2 trial; hence there are results validating its safety but none supporting efficacy."
How many participants are being considered for inclusion into this medical trial?
"Affirmative. Clinicaltrials.gov demonstrates that this medical trial is currently recruiting patients as of January 29th 2022, a year after it was initially posted on March 11th 2021. The research requires 65 participants to be recruited from one centre."
Has Pembrolizumab been tested in previous clinical trials?
"Presently, 1051 studies investigating pembrolizumab are underway. Of these investigations, 146 have reached the third phase of clinical trials. Though this drug is primarily tested in Scottsdale, Arizona, a staggering 43 790 unique locations are hosting Pembroilzumab research initiatives."
Is the recruitment of participants ongoing for this research effort?
"Affirmative. According to clinicaltrials.gov, this medical investigation is actively seeking participants since its initial post date on March 11th 2021 and last edit on January 29th 2022. 65 patients need to be recruited from one site of the study."
Share this study with friends
Copy Link
Messenger